HUE031860T2 - PCSK9 vakcina - Google Patents

PCSK9 vakcina Download PDF

Info

Publication number
HUE031860T2
HUE031860T2 HUE12759427A HUE12759427A HUE031860T2 HU E031860 T2 HUE031860 T2 HU E031860T2 HU E12759427 A HUE12759427 A HU E12759427A HU E12759427 A HUE12759427 A HU E12759427A HU E031860 T2 HUE031860 T2 HU E031860T2
Authority
HU
Hungary
Prior art keywords
seq
vaccine
pcsk9
sequence
amino acid
Prior art date
Application number
HUE12759427A
Other languages
English (en)
Inventor
Sylvia Brunner
Gergana Galabova
Bettina Wanko
Markus Windwarder
Gabriele Winsauer
Claudia Juno
Guenther Staffler
Original Assignee
Affiris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris Ag filed Critical Affiris Ag
Publication of HUE031860T2 publication Critical patent/HUE031860T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0012—Lipids; Lipoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Claims (5)

  1. SZABADALMI IGÉNYPONTOK 1. \akarna, umth legalább ke* fotamenst tanaimé* a Ffepuaem kommnv szabna* nn/kex in 9~es típusból (PCSKÓ), ahol a szóban forgé legalább két bagmens közül egy első íragmens egalább 9 egymást követő aminosav csoportot tartalmaz a PCSK.Ü 9. számó szekvencia szerinti 153* 65-ös anririosav csoportjai közük és a szóban forgó legalább két íragmens közül egy második ragmens legúobb <> e^vnam kővető ammoaax 0\of '· A t uodnw a Ft SKfo '> szaru* ^ekxemm deribti 20W22z~es aminosav csoportjai közül 2, \z 1 igénypont s/mmt xakoata, altot ci fop.mmo kel íram-mam a kővetkező annoosax. « ekxcnentsai rendelkező pctddvh közöl vaks/tjuk kr HÍXVH bill 1FPR (2 szarni! s.-ekxenda\ >V I;DGTRPHRQASK fo. számú szekvencia), FF.FIXFÍRFHRQA iá. számi! szekvenciák sEDOTRFHRQASK t'S. szama s/ekx ended F11 X > I RFI IRl) 4S \h s/ámn szekvencia), sfFWN) ΓΗΙΕ'Ή sz,anu'/elsendat es nIPWNí 1 RÍ i *,8 számú szekvencia).
  2. 3, Az: l. xa$\ 2 igeuxponf s/ermú vakcina, ahol a Fi $X9 legalább egy bagmeuseoek tmino&amp;tv szekvenciáját a következő csoportból választhatjuk ki;MPWNIERITPP&amp; (2- számú szek->envî«k MPWN1.ERII Is J. számú szel'·endet es RU*WM FRÜ (8 sz,mm szekumda) ;s a •W'SK.9 legalább egy hagmensének ammosav szekvenciáját áíkivetkezo csoporiMbvái^ifobliik ki:: Ul DO) Rí HRdd'-K ' *za<' vo\n^ ά o\ REFOSíf'RFe^A t.4 számú Sickvcndal, -Ti XI 1 kPHRi) XNk iá számú o Mvendo: ès H 1X11RI1 iR*> SS fo. számú szekvenciád 4. \z ige !^nfü! \ nointcHRo s*ctat‘t voicína, aboi t vaMnai a következő ammo* >av szekvenciákat tartalmazza: SfPW’NLERn RPR (2, számé szekvencia) ás PHBDOTRPHRQASiC ,3 szűnni s/cfoeneiak SFWVM 1 RÍ IPFE «3, szeme vekxeneía) és FLlllr* fRinklROA (4, számú szekvenciák SUAVNLFRíl FPR (3. számú széki ende) ès F FIXFl RFHRQASK (5 számú szekven-riak SIPWKLFR1TPPR. ez. számé szekvencia) és CEDfi ÍRHÍRQAS íé. számé szekvenda| PH nQ i'Rl HbdARR te. sz.mm -KS'em ,ri Ή’Ά'ΜΙΜΙΓ Π * zárna szessemnak sb ! 00 HU l'Rfo \$K d szarni \ze\^ éneid es SIFWMHRI1 H. számit s. oMendd. PBLDGTRFHRQA (4, .számú szekvencia) és SIPWNXFRríF tT. számú szekvenciái FBEOCjl RFHRQa iá. számú s ok ioné,,, > es ΗΡΑ \i 1 ΕΓ. H venu* szel vénem), bl Dd FRM trid \nK rê s ovseuend es HPWXLFRi ! F Π számú s/tlxemnay EKDO {'RfFIRdASK. t'S, számé szekvencia) c> blPWNLHRIT ázltúi szekvencia). •.BfXrrflPHRQAS (6, számú szekvencia) és SíbVéMLBiklTé {?, számé szekvencia) vagy iBÖ(;FíEf HRQAS (b. szárivá szeksfuoia) és SIPWMI^MT 4, szárié szekvencia) % Az ! -4. igénypontok bármelyike szerinti yákeina, ahol a., :Kl|K.f legalább bét ragmense egy eiszielmcsoportol iMtaltnaz a Béfemknálison és/eagy áz bi-tennipálisí>n, ti Az i-5, Igénypontok hámtelylke szerinti vakcina, áltól a PCSKif legalább két ragmense egy gyógyászanlag elfogadható hordozóhoz kapcsolódik, előnyösen Kl.B4n.rz tmrócsiga igmeíarttak
  3. 7, Az {-O, igénypontok bármelyike szennu \ukma. ahol a PCI'SKA legalább Mi tagmekse intiiiétmlMi, szubkntáa
  4. 8.. Az !-?. Igénypontok bánndyike szerinti vakcina, ahol a vakcina legalább egy djgvlnsi tarte!am% elony5|gn alumini«Bí'-yá^ld©)< g. Az 1-4, Igénypontok bármelyike szerinti vakcím alkalmazása karäiavaazkuläris he-épségé, mék .pÜll máriás eízárődásos betegség, s/iv koszorúér betegség, gutaőtéses agyi oznlíga vagy pefiH&amp;iia eátetepeg kézelésében és/vagy megelőzésében,
  5. 10. Vakcina 9. igénypont szerinti alkalmazik amelyben a FC$K9~s# legalább lit ragmensét adjuk be egy egyénnek Dől ne - 19 rogy etonyds$6 1 ug ~>(K1 pg per éozrs mennyiségben;.
HUE12759427A 2011-09-13 2012-09-13 PCSK9 vakcina HUE031860T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11181090.9A EP2570135B1 (en) 2011-09-13 2011-09-13 PCSK9 Vaccine

Publications (1)

Publication Number Publication Date
HUE031860T2 true HUE031860T2 (hu) 2017-08-28

Family

ID=46851983

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE11181090A HUE028583T2 (hu) 2011-09-13 2011-09-13 PCSK9 vakcina
HUE12759427A HUE031860T2 (hu) 2011-09-13 2012-09-13 PCSK9 vakcina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE11181090A HUE028583T2 (hu) 2011-09-13 2011-09-13 PCSK9 vakcina

Country Status (24)

Country Link
US (2) US9220762B2 (hu)
EP (2) EP2570135B1 (hu)
JP (1) JP6054400B2 (hu)
KR (1) KR101983685B1 (hu)
CN (1) CN103874504B (hu)
AU (1) AU2012307348B8 (hu)
BR (1) BR112014005756A2 (hu)
CA (1) CA2848487A1 (hu)
CY (2) CY1117335T1 (hu)
DK (2) DK2570135T3 (hu)
ES (2) ES2565757T3 (hu)
HR (2) HRP20160392T1 (hu)
HU (2) HUE028583T2 (hu)
IL (1) IL231043A (hu)
LT (1) LT2755678T (hu)
MX (1) MX346883B (hu)
PL (2) PL2570135T3 (hu)
PT (1) PT2755678T (hu)
RS (1) RS54639B1 (hu)
RU (2) RU2017139094A (hu)
SG (1) SG11201400086QA (hu)
SI (2) SI2570135T1 (hu)
SM (1) SMT201600082B (hu)
WO (1) WO2013037889A2 (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
EP3104877B1 (en) 2014-02-11 2020-01-22 The USA, as represented by The Secretary, Department of Health and Human Services Pcsk9 vaccine and methods of using the same
PL3110439T3 (pl) * 2014-02-28 2019-09-30 Affiris Ag Szczepionki PCSK9
CN105085684B (zh) * 2014-05-14 2020-04-17 上海亨臻实业有限公司 Pcsk9靶向重组疫苗设计及其应用
CN106822881A (zh) * 2016-12-09 2017-06-13 四川大学 一种针对pcsk9的抗高血脂蛋白疫苗
JP7050807B2 (ja) 2017-04-13 2022-04-08 カディラ ヘルスケア リミティド 新規ペプチドベースのｐｃｓｋ９ワクチン
CN107488215A (zh) * 2017-07-19 2017-12-19 邱志华 人前蛋白转化酶枯草溶菌素9免疫原性肽段及其载体疫苗
US20230093678A1 (en) * 2020-01-28 2023-03-23 Ubi Ip Holdings Peptide immunogens targeting pcsk9 and formulations thereof for prevention and treatment of pcsk9-mediated disorders
KR20210158693A (ko) * 2020-06-24 2021-12-31 바이오스트림테크놀러지스(주) 항 ｐｃｓｋ９ 항체 및 이의 용도
JPWO2022244845A1 (hu) * 2021-05-19 2022-11-24
WO2023161526A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5570806B2 (ja) * 2006-05-11 2014-08-13 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｐｃｓｋ９遺伝子の発現を阻害するための組成物および方法
KR20100019440A (ko) * 2007-04-13 2010-02-18 노파르티스 아게 프로-단백질 전환효소 서브틸리신/켁신 유형 ９ (ｐｃｓｋ９)를 조정하기 위한 분자 및 방법
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AT507604A1 (de) * 2008-11-19 2010-06-15 Affiris Forschungs & Entwicklungs Gmbh Behandlung von atherosklerose
PT2473605T (pt) * 2009-09-03 2018-05-28 Pfizer Vaccines Llc Vacina pcsk9

Also Published As

Publication number Publication date
BR112014005756A2 (pt) 2017-03-28
CA2848487A1 (en) 2013-03-21
AU2012307348A1 (en) 2014-03-20
DK2570135T3 (en) 2016-02-15
EP2755678B1 (en) 2016-12-21
KR101983685B1 (ko) 2019-05-29
US20160106822A1 (en) 2016-04-21
ES2618796T3 (es) 2017-06-22
EP2570135A1 (en) 2013-03-20
RU2017139094A (ru) 2019-02-12
RU2017139094A3 (hu) 2019-02-12
US20150071951A1 (en) 2015-03-12
MX2014002879A (es) 2014-04-10
ES2565757T3 (es) 2016-04-06
RU2014114506A (ru) 2015-10-20
RS54639B1 (en) 2016-08-31
JP6054400B2 (ja) 2016-12-27
EP2755678A2 (en) 2014-07-23
AU2012307348A8 (en) 2017-04-06
WO2013037889A3 (en) 2013-05-10
SMT201600082B (it) 2016-04-29
RU2640258C2 (ru) 2017-12-27
SI2755678T1 (sl) 2017-04-26
DK2755678T3 (en) 2017-03-13
CY1117335T1 (el) 2017-04-26
PL2570135T3 (pl) 2016-07-29
US9669079B2 (en) 2017-06-06
WO2013037889A2 (en) 2013-03-21
US9220762B2 (en) 2015-12-29
PL2755678T3 (pl) 2017-08-31
CN103874504B (zh) 2017-05-31
SG11201400086QA (en) 2014-03-28
JP2014527078A (ja) 2014-10-09
AU2012307348B8 (en) 2017-04-06
HUE028583T2 (hu) 2016-12-28
HRP20160392T1 (hr) 2016-05-06
CN103874504A (zh) 2014-06-18
CY1118856T1 (el) 2018-01-10
IL231043A (en) 2017-05-29
PT2755678T (pt) 2017-03-24
SI2570135T1 (sl) 2016-05-31
AU2012307348B2 (en) 2017-03-02
EP2570135B1 (en) 2016-01-27
IL231043A0 (en) 2014-03-31
NZ621439A (en) 2015-06-26
HRP20170328T1 (hr) 2017-05-19
MX346883B (es) 2017-04-05
LT2755678T (lt) 2017-03-27
KR20140067118A (ko) 2014-06-03

Similar Documents

Publication Publication Date Title
US9669079B2 (en) PCSK9 peptide combination vaccine and method of use
US11980657B2 (en) Peptide vaccines for hypercholesterolemia related diseases
US10004791B2 (en) Peptide vaccines against PCSK9
US20240197844A1 (en) Peptide vaccines usable for hypercholesterolemia related diseases
EP2532359A1 (en) CETP fragments
NZ621439B2 (en) Vaccine